A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

While GLP-1s like Ozempic and Wegovy are being widely prescribed for weight loss, doctors currently do not have a way to ...

One out of ten people don’t see the weight loss results they expect.

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...

Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced two ...

Oral GLP-1s are set to shake up the weight-loss drug market, but industry onlookers will be wondering how these new tablets might impact healthcare supply chains.

Companies confirm that markers of weight loss and glycemic control are distinct in preliminary study, with multiple mechanisms identified that provide opportunities to guide indication extension ...

The Centers for Medicare & Medicaid Services will launch the Medicare GLP-1 Bridge in July 2026, offering some Part D beneficiaries temporary access to GLP-1 drugs for weight loss alongside coverage ...

In animal studies, an experimental drug targeting both GIP and glucagon led to equal or greater weight loss compared to current treatments, depending on the dose, STAT News reported. Besides reducing ...

The KCAS Bio – Lyon, France Site Renews Its GLP Compliance Statement, Strengthening Its Support for IND-Enabling Studies Through Bioanalysis and Biomarkers KCAS Bio today announced that its European ...